Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Epidermal Growth Factor Receptor Mutations”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableLooking for participantsNCT06102928
What this trial is testing

A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R Mutation

Who this might be right for
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Kunming Medical University 30
Testing effectiveness (Phase 2)WithdrawnNCT02297425
What this trial is testing

Patients With EGFRm (Epidermal Growth Factor Receptor Mutant) Lung Cancer

Who this might be right for
Advanced EGFRm (Del 19 or L858R +/- T790M) NSCLC
Pfizer
Large-scale testing (Phase 3)Study completedNCT01667562
What this trial is testing

Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Hoffmann-La Roche 375
Testing effectiveness (Phase 2)UnknownNCT03799094
What this trial is testing

Vitamin C and Tyrosine Kinase Inhibitor in Lung Cancer Patients With Epidermal Growth Factor Receptor Mutations

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Clifford Hospital, Guangzhou, China 150
Testing effectiveness (Phase 2)UnknownNCT01608841
What this trial is testing

The Role of EGFR Mutations in Pancreatic Cancer Patients Receiving Gemcitabine With or Without Erlotinib

Who this might be right for
Metastatic Pancreatic Cancer
Taipei Veterans General Hospital, Taiwan 88
Large-scale testing (Phase 3)Study completedNCT01887886
What this trial is testing

Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 10
Large-scale testing (Phase 3)Active Not RecruitingNCT06074588
What this trial is testing

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC 556
Not applicableStudy completedNCT02047903
What this trial is testing

GIOTRIF in First Line Therapy of Advanced NSCLC With EGFR-mutations

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 161
Large-scale testing (Phase 3)Study completedNCT03653546
What this trial is testing

First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases

Who this might be right for
Non-small Cell Lung CancerEGFR Gene MutationBrain Metastases
Alpha Biopharma (Jiangsu) Co., Ltd. 492
Not applicableNot Yet RecruitingNCT05698264
What this trial is testing

A Pilot Study to Understand the Impact of Therapy With Tumour Treating Fields (TTFields) in NSCLC

Who this might be right for
Non Small Cell Lung CancerEGFR Gene MutationImmune Checkpoint Inhibitor
Nir Peled 50
Early research (Phase 1)Ended earlyNCT03065387
What this trial is testing

Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

Who this might be right for
Advanced Malignant Solid NeoplasmEGFR Gene AmplificationEGFR Gene Mutation+7 more
M.D. Anderson Cancer Center 84
Large-scale testing (Phase 3)Active Not RecruitingNCT02511106
What this trial is testing

AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.

Who this might be right for
Stage IB-IIIA Non-small Cell Lung Carcinoma
AstraZeneca 682
Testing effectiveness (Phase 2)Looking for participantsNCT04486833
What this trial is testing

Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib

Who this might be right for
Carcinoma, Non-Small Cell Lung
Genprex, Inc. 158
Testing effectiveness (Phase 2)Looking for participantsNCT06156527
What this trial is testing

Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & Smoker

Who this might be right for
Lazertinib
National Cancer Center, Korea 120
Testing effectiveness (Phase 2)UnknownNCT03151161
What this trial is testing

Intermittent and Maintenance of Icotinib in Combination With Pemetrexed/Carboplatin Compared With Icotinib Single Drug in Ⅲb/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation

Who this might be right for
Lung, Carcinoma
Sun Yat-sen University 118
Not applicableLooking for participantsNCT06127979
What this trial is testing

Changes in Ki67 Expression in People With Breast Cancer Receiving Endocrine Therapy Before Surgery

Who this might be right for
Breast Cancer
Memorial Sloan Kettering Cancer Center 42
Not applicableUnknownNCT01100827
What this trial is testing

A Retrospective Molecular Epidemiology Study in Singapore Patients With Advanced Non Small Cell Lung Cancer (NSCLC) of Adenocarcinoma Histology to Assess Epidermal Growth Factor Receptor (EGFR) Mutation Status

Who this might be right for
NSCLC
National University Hospital, Singapore
Testing effectiveness (Phase 2)Active Not RecruitingNCT05546866
What this trial is testing

Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm

Who this might be right for
Non-small Cell Lung Cancer
AstraZeneca 51
Large-scale testing (Phase 3)Study completedNCT01342965
What this trial is testing

Erlotinib (Tarceva) Versus Gemcitabine/Cisplatin as First-line Treatment in Patients With Non-small Cell Lung Cancer With EGFR Mutations

Who this might be right for
Non-Small Cell Lung Cancer
Hoffmann-La Roche 217
Testing effectiveness (Phase 2)UnknownNCT03062800
What this trial is testing

Study of Thalidomide in Treatment of Advanced Nsclc (Dream-003)

Who this might be right for
Advanced Nsclc
Qilu Hospital of Shandong University 232
Next Page